X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tumorad (177Lu]Lu-SN201) is a ionisisng radiation emmiter which is under phase 1/2 clinical development for the treatment of advanced cancer,
Lead Product(s): [177Lu]Lu-SN201
Therapeutic Area: Oncology Product Name: Tumorad
Highest Development Status: Phase I/ Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
The investigational drug candidate from Sapgo, 177Lu-SN201, a radio-labeled compound, is currently undergoing evaluation in Phase I/II clinical trial studies with patients for treating advanced solid tumors.
Lead Product(s): 177Lu-SN201
Therapeutic Area: Oncology Product Name: 177Lu-SN201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
177Lu-SN201 has been optimally designed for physiological targeting by means of the EPR effect. Preclinical results from different tumor models confirm accumulations in tumors, inhibited tumor growth and extended survival.
Lead Product(s): 177Lu-SN201
Therapeutic Area: Oncology Product Name: 177Lu-SN201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
177Lu-SN201 is clinically effective against cancer. Combined with Spago Nanomedical´s carefully designed polymeric nanomaterial, the candidate promising new radionuclide therapy for physiological targeting and tumor selective treatment of cancer.
Lead Product(s): 177Lu-SN201
Therapeutic Area: Oncology Product Name: 177Lu-SN201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
The study will evaluate the safety and MRI enhancing properties of SN132D in participants with suspected endometriosis. Comparisons will be made to transvaginal ultrasound and conventional MRI in order to consider the diagnostic potential of SN132D in endometriosis.
Lead Product(s): SN132D
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SN132D
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
In a mouse model for breast cancer, Spago has shown that Tumorad® significantly reduces tumor growth and prolongs survival. Based on this and previously communicated progress in the project, Spago has nominated Tumorad® or SN201 for Pre-clinical safety tests.
Lead Product(s): Tumorad-Lu177
Therapeutic Area: Oncology Product Name: SN201
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
